Skip to content
Low Dose GLP-1Providers

Provider review

Trimi review

Built around microdosing itself, at one flat monthly price.

Low, metabolic-baseline dosing is the whole programme rather than the first rung of a titration ladder.

Price as published

Flat monthly pricing for low-dose compounded semaglutide or tirzepatide, with no separate membership or lab fee (confirm the current rate on Trimi's site before starting).

Visit Trimi

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

The verdict

Trimi is one of the few programmes here designed around microdosing rather than accommodating it — small, appetite- and baseline-oriented amounts, at a single flat monthly price with no membership stacked underneath. That structure is the point, and it is a genuinely good one for this audience. It is also a leaner offering than the top of this board: the compounding pharmacy is not named publicly, so you cannot verify the facility the way you can with a clearly identified 503A, and there is no included registered-dietitian programme.

The trade-off we would want you to read first

The compounding pharmacy is not named publicly, so you cannot verify the facility the way you can with a clearly identified 503A

Who it suits, and who it does not

A good fit if

  • You want a provider whose default is a low dose, not one you have to talk down
  • You want one number per month with nothing billed beside it
  • You do not need coaching or dietitian support bundled in

Look elsewhere if

  • You want to know which pharmacy is compounding your medication
  • You want included human support rather than a shipped vial
  • You want a brand-name pathway available if you change your mind

How the programme works

An online intake is reviewed by a licensed provider, then a low-dose compounded semaglutide or tirzepatide protocol is shipped to you. Trimi is built specifically around microdosing — small, appetite- and metabolic-baseline-oriented amounts rather than aggressive titration — and folds the medication into a single flat monthly price with no separate membership stacked on top. It is a leaner offering than CoreAge: strong on price structure, lighter on named-pharmacy transparency and included human support.

At a glance

Pricing structure
Flat at every dose
Consult
Included in the price
Compounding
Not publicly identified
Labs
Not required
Dietitian support
Not included

Strengths

  • One flat monthly price with no separate membership or lab fee stacked on the medication
  • Explicitly microdose-first — low, metabolic-baseline dosing rather than max-dose weight-loss marketing
  • Licensed-clinician review of the online intake before anything ships

The other trade-offs

  • Compounded-only — no brand-name Wegovy or Zepbound pathway, and compounded GLP-1s are not FDA-approved
  • Lighter human support — no included registered-dietitian program like CoreAge's nurse-and-RD consults
  • Like all intentional GLP-1 microdosing, the approach is off-label and unproven (see our evidence review)

Before you buy

Intentional GLP-1 microdosing is off-label and unproven — no randomised trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

Where this sits on the board

Trimi is one of 24 low-dose GLP-1 providers we track. The board lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.

Funding & disclosures

  • A number of links are affiliate or referral links.
  • Begin treatment through one and we may earn a commission via the Katalys network — at no added cost to you.
  • What we write about a provider is the same either way — unflattering findings about one that pays us stay in.
  • Full detail: disclosure page.